Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Riociguat

FDA-approved product (tablet, oral), marketed as Adempas, Riociguat.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Riociguat
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hypertension
  • Idiopathic and/or familial pulmonary arterial hypertension
  • Pulmonary arterial hypertension
  • Pulmonary hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antihypertensives for pulmonary arterial hypertension
FDA pharmacologic class
Soluble Guanylate Cyclase Stimulator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis68.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Riociguat in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Riociguat with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

    NCT02191137 · start 2014-09-23

    Registered record
    Registry ID
    NCT02191137
    Conditions
    Hypertension, Pulmonary
    Interventions
    Riociguat (Adempas, BAY63-2521)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-09-23
    Completion
    2016-07-16
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionRiociguat (Adempas, BAY63-2521)
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

    NCT02138825 · start 2014-06-04

    Registered record
    Registry ID
    NCT02138825
    Conditions
    Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
    Interventions
    Riociguat (Adempas, BAY63-2521); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-06-04
    Completion
    2016-09-14
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Interstitial Pneumonias / Hypertension,Pulmonary
    InterventionRiociguat (Adempas, BAY63-2521); Placebo
    PhasePhase 2
    Registry statusTerminated

  • Relative Bioavailability Study

    NCT02159313 · start 2014-06

    Registered record
    Registry ID
    NCT02159313
    Conditions
    Healthy Volunteers
    Interventions
    Riociguat(Adempas,BAY63-2521)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-06
    Completion
    2015-01
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionRiociguat(Adempas,BAY63-2521)
    PhasePhase 1
    Registry statusCompleted

  • EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension

    NCT02092818 · start 2014-05-31

    Registered record
    Registry ID
    NCT02092818
    Conditions
    Hypertension, Pulmonary
    Interventions
    Riociguat (Adempas, BAY63-2521)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-05-31
    Completion
    2018-06-29
    Enrolment
    1,316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionRiociguat (Adempas, BAY63-2521)
    PhaseNot recorded
    Registry statusCompleted

  • Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH

    NCT02094001 · start 2014-05

    Registered record
    Registry ID
    NCT02094001
    Conditions
    Chronic Thromboembolic Pulmonary Hypertension
    Interventions
    Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-05
    Completion
    2016-06
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Thromboembolic Pulmonary Hypertension
    InterventionCardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)
    PhasePhase 2
    Registry statusCompleted

  • Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor

    NCT02007629 · start 2014-02-18

    Registered record
    Registry ID
    NCT02007629
    Conditions
    Hypertension, Pulmonary
    Interventions
    Riociguat (Adempas, BAY63-2521)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-02-18
    Completion
    2016-12-29
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionRiociguat (Adempas, BAY63-2521)
    PhasePhase 3
    Registry statusCompleted

  • Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator

    NCT01926847 · start 2013-10

    Registered record
    Registry ID
    NCT01926847
    Conditions
    Raynaud Disease
    Interventions
    Riociguat (Adempas, BAY63-2521); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-10
    Completion
    2014-06
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRaynaud Disease
    InterventionRiociguat (Adempas, BAY63-2521); Placebo
    PhasePhase 2
    Registry statusCompleted

  • Coronary Vasomotor Response After Riociguat Exposure

    NCT01165931 · start 2012-05

    Registered record
    Registry ID
    NCT01165931
    Conditions
    Coronary Artery Disease
    Interventions
    Riociguat (BAY63-2521)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2012-05
    Completion
    2013-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionRiociguat (BAY63-2521)
    PhasePhase 2
    Registry statusWithdrawn

  • Relative Bioavailability and Food Effect Study

    NCT01489488 · start 2012-01

    Registered record
    Registry ID
    NCT01489488
    Conditions
    Pharmacology, Clinical
    Interventions
    Riociguat (BAY63-2521); Riociguat (BAY63-2521); Riociguat (BAY63-2521); Riociguat (BAY63-2521); Riociguat (BAY63-2521)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-01
    Completion
    2012-05
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacology, Clinical
    InterventionRiociguat (BAY63-2521); Riociguat (BAY63-2521); Riociguat (BAY63-2521); Riociguat (BAY63-2521) +1 more
    PhasePhase 1
    Registry statusCompleted

  • Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

    NCT01266265 · start 2010-12

    Registered record
    Registry ID
    NCT01266265
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    inhaled prostacyclin; inhaled prostacyclin; prostacyclin; subcutaneous and intravenous prostacyclin; oral ERA; oral PDE5 inhibitors
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-12
    Completion
    2014-12
    Enrolment
    1,333

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    Interventioninhaled prostacyclin; inhaled prostacyclin; prostacyclin; subcutaneous and intravenous prostacyclin +2 more
    PhaseNot recorded
    Registry statusCompleted

  • Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.

    NCT01179334 · start 2010-08

    Registered record
    Registry ID
    NCT01179334
    Conditions
    Pulmonary Hypertension
    Interventions
    Riociguat (Adempas, BAY63-2521); Placebo; Sildenafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-08
    Completion
    2013-05
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Hypertension
    InterventionRiociguat (Adempas, BAY63-2521); Placebo; Sildenafil
    PhasePhase 2
    Registry statusCompleted

  • A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction

    NCT01172756 · start 2010-07

    Registered record
    Registry ID
    NCT01172756
    Conditions
    Hypertension, Pulmonary; Ventricular Dysfunction, Left
    Interventions
    Riociguat (BAY63-2521); Riociguat (BAY63-2521); Riociguat (BAY63-2521); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-07
    Completion
    2012-10
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary; Ventricular Dysfunction, Left
    InterventionRiociguat (BAY63-2521); Riociguat (BAY63-2521); Riociguat (BAY63-2521); Placebo
    PhasePhase 2
    Registry statusTerminated

  • Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

    NCT04364464 · start 2010-02-19

    Registered record
    Registry ID
    NCT04364464
    Conditions
    Clinical Pharmacology
    Interventions
    Riociguat (Adempas, BAY 63-2521)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-02-19
    Completion
    2011-09-20
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Pharmacology
    InterventionRiociguat (Adempas, BAY 63-2521)
    PhasePhase 1
    Registry statusCompleted

  • BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension

    NCT00863681 · start 2009-03-12

    Registered record
    Registry ID
    NCT00863681
    Conditions
    Hypertension, Pulmonary
    Interventions
    Riociguat (BAY63-2521)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-03-12
    Completion
    2019-08-19
    Enrolment
    396

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionRiociguat (BAY63-2521)
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

    NCT00855465 · start 2009-02-23

    Registered record
    Registry ID
    NCT00855465
    Conditions
    Pulmonary Hypertension
    Interventions
    Riociguat (Adempas, BAY63-2521); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-02-23
    Completion
    2012-06-27
    Enrolment
    262

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Hypertension
    InterventionRiociguat (Adempas, BAY63-2521); Placebo
    PhasePhase 3
    Registry statusCompleted